SGMO
0.20 USD
+36.36%
Today
+36.36%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 11:00 PM
Tue
4:30 PM ~ 11:00 PM
Wed
4:30 PM ~ 11:00 PM
Thu
4:30 PM ~ 11:00 PM
Fri
4:30 PM ~ 11:00 PM
Sat
Closed
Information
Name
Sangamo Therapeutics Inc. Leverage
Currency
USD
Standard Leverage
1X
Enhanced Leverage
2X
Overnight Fees Buy
-0.0183%
Overnight Fees Sell
0.0016%
Market Cap
30.66M
Avg Daily Volume
6.34M
52 Week High
0.766 USD
52 Week Low
0.0637 USD
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01830% | $(0.183) |
| SELLS | 0.00160% | $0.016 |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Top News
ALRAJHI
-0.23%
SNB
-0.18%
SABIC-AGRI-NUTRIENTS
-0.96%
SAUDI.ARAMCO
-0.86%
AIRA
-0.55%
ALDAR
+0.50%
ENBD
-0.32%
FAB
+0.00%
QNBK
-0.12%
MIDEAST STOCKS-Most Gulf markets retreat on stalled US-Iran peace efforts
reuters.com
2mo ago
ALRAJHI
-0.23%
SAUDI.ARAMCO
-0.86%
AIRA
-0.55%
ALDAR
+0.50%
EMAR
-0.67%
QISB
-0.85%
SALIK
-1.93%
MIDEAST STOCKS-Middle Eastern bourses fall on renewed US-Iran tensions
reuters.com
2mo ago
AIRA
-0.55%
ALDAR
+0.50%
ENBD
-0.32%
QNBK
-0.12%
EMAR
-0.67%
MAADEN
-1.64%
MIDEAST STOCKS-Gulf bourses gain on optimism for US-Iran peace talks
reuters.com
2mo ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
